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Skeletal muscle possesses a remarkable
self-repair capacity whose underlying
mechanisms have been thoroughly inves-
tigated (Vandenburgh et al., 1988; De
Arcangelis et al., 2003; Musaro et al., 2007;
Moresi et al., 2008, 2009) with a view to
stimulating in situ regeneration. It is, how-
ever, unable to restore volumetric tissue
loss as a consequence of trauma, congeni-
tal defects, ablation, or denervation. This
is the rationale behind the creation of new
skeletal muscle through tissue engineering
(TE).While most review articles announce
that skeletal muscle TE is advancing and
is readily translatable, it seems clear that
engineered skeletal muscle is still lagging
far behind other tissues if placed within
a clinical practice context. Why is it not
yet possible to transplant off-the-shelf,
functional muscles into patients?
Major difficulties encountered in skele-
tal muscle TE on the whole organ scale are
currently being addressed. These include
the following: the large size of human
organs has been overcome by studies
on rabbit, dogs and humans (Badylak
et al., 1998; Rossi et al., 2010; Badylak
et al., 2013); numerous myogenic cell
populations of muscle and non-muscle
origin (Rossi et al., 2010) are now avail-
able as cell sources; scaffolds with a spe-
cific 3D orientation are obtained through
organ decellularization, freeze drying and
electrospinning of synthetic or natural
materials (Klumpp et al., 2010); func-
tion has been proven for several of these
engineered muscle constructs (Mudera
et al., 2010; Carosio et al., 2013). Even
some of the interactions between mus-
cle and other organs have been addressed:
the muscular-tendinous junction can be
restored by suturing the residual ten-
don proximal extremity of muscle-derived
acellular scaffolds to the host tendon
(Perniconi et al., 2011); the vascular bed
can be reconstructed in striated muscles
(Koffler et al., 2011; Carosio et al., 2013),
particularly if the elegant approach pro-
posed by Ott et al. for decellularized heart
is applied (Ott et al., 2008).
Muscles, however, remain very chal-
lenging organs to rebuild. Muscle hierar-
chic architecture and heterogeneous cell
composition have not yet been suffi-
ciently investigated by either in vitro or
in vivo studies. Moreover, innervation by
the somato-motor system has not been
addressed at all. We believe that the lat-
ter issue will be the hardest to address;
since we are still unable to induce nor-
mal re-innervation following motor neu-
ron injury, the successful innervation of a
new, pre-built organ transplanted in vivo
is unlikely to be straightforward. Lastly,
even some basic aspects of muscle TE,
such as graft bioactivity and integration,
which are often claimed to be established,
are actually still poorly understood; for
instance, the novel idea of cryptic pep-
tides released by the extra-cellular matrix
(ECM) while it is being biodegraded and
remodeled (Grayson et al., 2009) opens
new avenues for the exploration of ECM
component bioactivity. This need to gain
a better knowledge of the properties of the
ECM and bioactive molecules used in TE
applications is indeed the rationale of ded-
icated publications, such as this Frontiers
in Muscle Physiology Special Issue.
While obtaining a fully functional,
innervated human skeletal muscle from
TE that may be used for clinical purposes
remains a long-term goal, here we propose
two applications for engineered muscle
that are no less ambitious and that may be
achieved and exploited in the short term.
As stated by Grayson et al., the biomimetic
effort being made within the context of
skeletal muscle TE is mostly aimed at: (a)
the creation of functional tissue grafts for
regenerative medicine applications in vivo;
(b) the generation of experimental models
in vitro for studies on stem cells, devel-
opment, and disease (where engineered
tissues can serve as advanced 3D models).
(a) As far as organ replacement in vivo
is concerned, we expect very spe-
cific TE-based interventions, such as
the application of muscle flaps and
the generation of minute individual
muscles, to be immediately success-
ful, whereas the mass production of
large muscles involved in chronic and
global muscle wasting diseases is less
unlikely to be so. One example of
organ replacement that is likely to
be successful is the Stapedius, which
is the smallest and weakest skeletal
muscle in the human body. It stabi-
lizes the stapes, a very small bone in
the inner hear, and is innervated by
the facial nerve. Dysfunctions in the
Stapedius induce hyperacusis or other
sound perception defects that are clin-
ically relevant. While the problem of
innervation is likely to persist, the
engineering and grafting of this small
and simple muscle to replace the dis-
eased one (often due to a local defect)
appears to be highly feasible.
(b) As far as in vitro studies are concerned,
it is self-evident that bidimensional
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cultures are very limited insofar as the
physiological 3D tissue organization
they yield is somewhat approximate.
Muscle TE was initially designed for
in vitro studies, when Vandenburgh
et al. introduced the 3D cultivation
of primary myoblasts in collagen gel
and generated contracting muscle tis-
sue in vitro for the first time in 1988
(Vandenburgh et al., 1988). A pro-
gressive increase in the architectural
complexity of ECM and cells in tissue-
culture grade constructs is likely to
provide adequate experimental mod-
els for the in vitro study of phenom-
ena that are specific to the in vivo
situation [e.g., stem cell niche, tissue
regeneration, aging (Sharples et al.,
2012)].
With regard to the two applications
described above, it should be borne in
mind that the goals and approaches
involved in building engineered muscle
tissue may not be the same owing to the
significant differences between in vitro and
in vivo TE strategies (reviewed by Rossi
et al., 2010).
For all these reasons, we believe that
the best bet for skeletal muscle TE is to
focus on specific, anatomically defined
solutions or on 3D in vitro modeling
of muscle tissue for basic and applied
research. We are confident that we will
eventually be able to transform the black
beast (i.e., striated muscle tissue engineer-
ing) into the best bet (i.e., a successful
clinical practice based on engineered mus-
cles). However, for more ambitious muscle
TE applications, there may still be a long
way to go.
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